Please visit Google Scholar for a full list of Sellers Lab publications.

Season 2, episode 4: Making it personal: Targeted cancer therapies – dana-farber. Dana. (n.d.).

Selected key publications:

Huang, HT., Lumpkin, R.J., Tsai, R.W., …, Sellers. W.R. Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates. Nat Chem Biol (2024). PDF

Chang, Liang, Nancy Y. Jung, Adel Atari, Diego J. Rodriguez, Devishi Kesar, Tian-Yu Song, Matthew G. Rees, …, and William R. Sellers. 2023. “Systematic Profiling of Conditional Pathway Activation Identifies Context-Dependent Synthetic Lethalities.” Nature Genetics, PDF

Loi, Sherene, Jeffrey Settleman, Johanna A. Joyce, C. S. Pramesh, Rene Bernards, Jia Fan, Juanita L. Merchant, Javid Moslehi, and William R. Sellers. 2023. “The next Big Questions in Cancer Research.” Cell 186 (8): 1523–27. PDF

Bondeson, D.P., Mullin-Bernstein, Z., Oliver, S., …, Sellers WR and Alessandra Ianari. Systematic profiling of conditional degron tag technologies for target validation studies. Nat Commun 13, 5495 (2022). PDF

Vazquez, F., and W. R. Sellers. 2021. “Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?” Cancer Research 81 (23): 5806–9.

Li, R., Klingbeil, O., Monducci, …, Sellers WR. Comparative optimization of combinatorial CRISPR screens. Nat Commun 13, 2469 (2022). PDF

Liang Chang, Paloma Ruiz, Takahiro Ito, William R. Sellers. Targeting pan-essential genes in cancer: Challenges and opportunities. Cancer Cell. 2021. PDF

Ito T, Young MJ, Li R, …, Sellers WR. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nat Genet. 2021. PDF

Mulvaney KM, Blomquist C, Acharya N, …, Sellers WR. Molecular basis for substrate recruitment to the PRMT5 methylosome. Mol Cell. 2021 Aug; PDF

McKinney DC, McMillan BJ, Ranaghan MJ, …, Sellers WR*, Ianari A*. Discovery of a First-in-Class Inhibitor of the PRMT5–Substrate Adaptor Interaction. J Med Chem. 2021 Aug; PDF

Atack TC*, Raymond DD, Blomquist CA, …, Sellers WR*. Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35. ACS Med Chem Lett. 2020, 11, 2131−2138. PMID: 33209191. PDF

Zamanighomi M†, Jain SS†, Ito T, …, Sellers WR. GEMINI: a variational Bayesian approach to identify genetic interactions from combinatorial CRISPR screens. Genome Biol. 2019 Jul 12;20(1):137. PMID: 31300006. PDF

Ghandi M†, Huang FW†, Jané-Valbuena J, …, Garraway LA*, Sellers WR*. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 May;569:503-508 PMID: 31068700. PDF

Li H, Ning S, Ghandi M, Kryukov GV, …, Schreiber SL, Clish CB, Garraway LA, Sellers WR. The landscape of cancer cell line metabolism. Nat Med. 2019 May;25(5):850-860. PMID: 31068703. PDF

McDonald ER 3rd†, de Weck A†, Schlabach MR†, Billy E*, …, Hofmann F*, Schmelzle T*, Sellers WR*. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell. 2017 Jul 27;170(3):577-592. PMID: 28753431. PDF

Wylie AA, Schoepfer S, Jahnke W, …, Sellers WR. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL. Nature. 2017 Mar 30;543:733-737. PMID: 28329763. PDF

Chen YP, LaMarche MJ, Chan H, …, Sellers WR*, Stams T*, Fortin PD*. Allosteric inhibition of SHP2 inhibits the transformed phenotype of RTK driven cancers. Nature. 2016;535:148-152 PMID: 27362227. PDF

Mavrakis KJ†, McDonald III ER†, Schlabach MR†, Billy E†, Hoffman GR†, …, Keen N, Schmelzle T, Hofmann F, Stegmeier F*, Sellers WR *. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016 Mar 11;351(6278):1208-13. PMID: 26912361. PDF

Gao H†, Korn JM†, Ferretti S, …, Williams JA* & Sellers WR*. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015 Oct 19. PMID: 26479923. PDF

Barretina J†, Caponigro G†, Stransky N, …, Sellers WR*, Schlegel R*, Garraway LA*.The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28;483:603-7. PMCID: PMC3320027. PDF

Beroukhim R†, Mermel CH†, Porter D, Wei G, Raychaudhuri S, Donovan J, …, Golub TR, Lander ES*, Getz G*, Sellers WR*, Meyerson M*. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463: 899–905. doi:10.1038/nature08822

Beroukhim R†, Getz G†, Nghiemphu L, Barretina J, Hsueh T, Linhart D, …, Meyerson M, Golub TR, Lander ES*, Mellinghoff IK*, Sellers WR*. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007;104: 20007–20012. doi:10.1073/pnas.0710052104

Beroukhim R†, Lin M†, Park Y, Hao K, …, Sellers WR*, Li C*. Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays. PLoS Comput Biol. 2006 May;2(5):e41. PMID: 16699594. PDF

Garraway LA, Widlund HR, Rubin MA, …, Sellers WR. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 7;436(7047):117-22. PMID: 16001072. PDF

Paez JG†, Jänne PA†, Lee JC†, …, Sellers WR*, Johnson BE*, Meyerson M*. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4;304(5676):1497-500. PMID: 15118125. PDF

Majumder PK, Febbo PG, Bikoff R, …, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004 Jun;10(6):594-601. PMID: 15156201. PDF

Singh D†, Febbo PG†, Ross K, …, Golub TR*, Sellers WR*. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002 Mar;1(2):203-9. PMID: 12086878. PDF

† These authors contributed equally

* These authors co-directed the work

Comments are closed.